QuantuMDx Group Ltd.
Point-of-care assays support personalized medicine
This article was originally published in Start Up
QuantuMDx Group Ltd. is developing handheld and portable low-cost diagnostic, genomic sequencing, and proteomic platforms that it thinks will promote the practice of personalized medicine in both developed and developing countries. The company aims to create devices that can provide results within minutes at point-of-care without the need for complex sample preparation processes, and that can integrate with mobile apps for ongoing patient support and education.
You may also be interested in...
Emerging Company Profile: Gadeta, a Dutch spin-out from University Medical Centre Utrecht, launched earlier this year to develop modified T-cell-based therapies that target metabolic dysregulation in solid and hematological malignancies.
PeptiMimesis is developing first-in-class transmembrane therapeutic peptides with potential in immuno-oncology, oncology and immune diseases. Its technology is based on research showing that targeting the transmembrane domain using a single peptide can block several of the processes involved in the development of cancer by disrupting dimerization of target receptors, impairing the formation of receptor complexes and indirectly blocking the subsequent signaling pathways
Redx Pharma PLC and its subsidiaries are focused on developing proprietary, small-molecule therapeutics to address areas of high unmet medical need principally in cancer, infection and autoimmune disease.